EyePoint Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
EYPT$0.36+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(In thousands except per share data)
| Year ended | ||
|---|---|---|
| December 31, | ||
| 2024 | 2023 | |
| Revenues: | ||
| Product sales, net | $3,164 | $14,232 |
| License and collaboration agreements | 38,496 | 30,797 |
| Royalty income | 1,613 | 989 |
| Total revenues | 43,273 | 46,018 |
| Operating expenses: | ||
| Cost of sales | 3,712 | 4,632 |
| Research and development | 132,926 | 64,662 |
| Sales and marketing | 131 | 11,689 |
| General and administrative | 52,358 | 40,102 |
| Total operating expenses | 189,127 | 121,085 |
| Loss from operations | (145,854) | (75,067) |
| Other (expense) income: | ||
| Interest and other income, net | 15,088 | 6,949 |
| Interest expense | (14) | (1,247) |
| Loss on extinguishment of debt | — | (1,347) |
| Total other income, net | 15,074 | 4,355 |
| Net loss before income taxes | $(130,780) | $(70,712) |
| Provision for income taxes | $(90) | $(83) |
| Net loss | $(130,870) | $(70,795) |
| Net loss per share: | ||
| Basic and diluted | $(2.32) | $(1.82) |
| Weighted average common shares outstanding: | ||
| Basic and diluted | 56,298 | 38,904 |
| Net loss | $(130,870) | $(70,795) |
| Other comprehensive gain (loss): | ||
| Unrealized gain (loss) on available-for-sale securities | 164 | 78 |
| Comprehensive loss | $(130,706) | $(70,717) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.